RxDoctor Payments Data

Eric van Meter, OD

Optometrist · Aurora, CONPI 1881332914

Payments from drug & device makers

$3,728in general payments, 2019–2025

Across 117 payments — averaging $31.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$462
  • Mallinckrodt Hospital Products Inc.$420
  • Alcon$393
  • Bausch & Lomb Americas Inc.$372
  • Tarsus Pharmaceuticals, Inc.$313
  • Dompe US, Inc.$294
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,61197%
  • Education$1003%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,728 in reported general payments places this provider in the 90th percentile of 1,025 optometrist providers in Colorado.

See all optometrist providers in Colorado

Medicare billing

Part B allowed, 2024
$85,200
Medicare patients
416
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner14$27,765
XiidraLifitegrast19$27,117
RestasisCyclosporine19$19,422
LumiganBimatoprost16$7,076
SimbrinzaBrinzolamide/Brimonidine Tart12$2,535
FlarexFluorometholone Acetate11$1,324
Timolol Maleate27$1,185
Latanoprost63$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$313$27,76514 claims
Bausch & Lomb Americas Inc.Xiidra$372$27,11719 claims
AbbVieRestasis, Lumigan$150$26,49835 claims
AlconSimbrinza$393$2,53512 claims
Eyevance Pharmaceuticals LLCFlarex$22$1,32411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,025 optometrist providers in Colorado.

Other optometrist in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →